TherapeuticsMD, Inc.

TXMD

US88338N2062

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.86 ^USD	-0.53%		0.00%	-17.33%

Mar. 29	TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 06	Knight Therapeutics Announces Launch of Bijuva in Canada	MT

TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Growth Index

June 23, 2023 at 12:00 am EDT

Latest news about TherapeuticsMD, Inc.

TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Knight Therapeutics Announces Launch of Bijuva in Canada	Feb. 06	MT
Knight Therapeutics Announces Product Launch For IMVEXXY In Canada	Jan. 04	MT
North American Morning Briefing : Stocks Seen Building on CPI Rally; PPI Data Due	Nov. 15	DJ
TherapeuticsMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
TherapeuticsMD, Inc. Announces Evaluation of Strategic Alternatives	Nov. 13	CI
TherapeuticsMD, Inc. Announces Executive Changes	23-08-18	CI
TherapeuticsMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures -2-	23-08-14	DJ
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Growth Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Value Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Value Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Growth Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Index	23-06-23	CI
TherapeuticsMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
TherapeuticsMD, Inc. announced that it expects to receive $5 million in funding from Rubric Capital Management LP	23-04-30	CI
TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-07	CI
TherapeuticsMD, Inc. Auditor Raises 'Going Concern' Doubt	23-04-06	CI
North American Morning Briefing : Stocks Seen -2-	23-03-30	DJ
North American Morning Briefing : Traders Reassess -2-	23-03-23	DJ
North American Morning Briefing : Some Calm -2-	23-03-16	DJ
Cantor Fitzgerald Reinstates TherapeuticsMD at Neutral With $5 Price Target	23-01-11	MT
TherapeuticsMd, Inc. Announces Chief Executive Officer Changes	23-01-06	CI
TherapeuticsMd, Inc. Announces Executive Changes	23-01-06	CI

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
THERAPEUTICSMD, INC.	-17.33%	21.45M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B

Specialty & Advanced Pharmaceuticals